

**CANCER  
HOSPITAL**  
WATTANOSOTH



**2019**

# **Wattanosoth Cancer Registry**



# Table of

## Contents



Message from Directo	1
Message from PCG Director of Cancer	2
Cancer Registry 2019 : Abstract	3
Annual Cancer Registry 2019	4
<i>Distribution of All Cancer by Age and Gender,</i>	
<i>The Top 10 Leading Site of Cancer,</i>	
<i>Patient Category of All Cancer,</i>	
<i>Method of Diagnosis, Staging, Primary,</i>	
<i>Patient Follow up, Patient Nationality, The Top 10</i>	
<i>Leading Site of Thai Patient Cancer, The Top 10</i>	
<i>Leading Site of Non-Thai Patient Cancer</i>	
Review of Breast Cancer	17
Review of Lung Cancer	22
Review of Colorectal Cancer	27
Review of Prostate Cancer	32
Review of Hepatobiliary Cancer	37
Hematologic Malignancies 2019	42
Age Distribution in All Male Cancer Number of Case	58
Age Distribution in All Female Cancer Number of Case	60
Breast Cancer Survival rate	63
Colorectal Cancer Survival rate	66
Lung Cancer Survival rate	69



Message from



## Director

Wattanosoth Hospital is dedicated to provide the best cancer care, leading in excellence services as comprehensive cancer center. 360° Cancer care is providing Prevention, Early detection, Treatment, Palliative care, and Survivorship.

The 2019 Cancer Registry Year Book by Wattanosoth Hospital is systematically collected the vital data regarding cancer diseases with the most up-to-date information on cancer.

Going forward, we are realizing our vision to be the most admired professional cancer care. We are working conscientiously to strengthen our deliver service beyond excellence and building our team with an intense focus on our values and a high-performing culture. We are confident in our future and enthusiastically embrace the innovations that will redefine our profession in the years to come.

(Visiting Prof.Dr.Thiravud Khuhaprema)  
Hospital Director of Wattanosoth cancer hospital





Message from



## PCG Director of Cancer



Cancer registry is an important part that can be used for cancer control and epidemiological study or research, program planning and for patient care improvement for each institute, each region or country depend on base of the data collection.

Bangkok Hospital Headquarter (BHQ) by Bangkok cancer Hospital, Wattanosoth has own systematically collected data regarding all cancer since 2006. We collected our hospital-based cancer statistic, evaluated the pattern of imaging, method of tissue diagnosis and multidisciplinary teams management.

A few years later, we start to develop Clinical Care Program Certification (CCPC) for breast cancer, Guideline for Lung and Colorectal cancer pathway. Until now, we have reported our cancer management outcome. In this near future, we are planning to develop for Prostate cancer, Cervical cancer and Head/Neck cancer pathway.

I sincerely thank my Hospital director and our staffs who contribute their invaluable work.

Assoc Prof Prasert Lertsanguansinchai ,M.D.  
PCG director, Bangkok cancer Hospital, Wattanosoth



# Cancer Registry 2019 :



## Abstract

The total of new cases diagnosed as a malignancy at Bangkok Hospital Headquarter (BHQ) is 2,249 cases (Tumor registry is 2,111 cases and Hematologic malignant is 138 cases). There was a little bit increased (7%) in the total number as compared to 2,088 cases in 2018.

The sex ratio is 1:1 This age distribution has not changed since the year 2018. Patients who are between 45-74 y/o are the majority accounting for more than half of the total. The average age in male patients is 55-74 y/o. which is slightly older than the female age of 45-64 y/o.

Top 5 malignancies are:

- |   |   |
|---|---|
| 1) Breast (Included DCIS) - 23.65 percent | 4) Prostate - 7.38 percent                |
| 2) Lung - 10.67 percent                   | 5) Liver and Hepatobiliary - 7.16 percent |
| 3) Colorectal - 8.94 percent              |   |

The trend for the top 5 malignancies has not changed over the past 10 years (2006-2018). For the past 10 years the top 5 have been: **Breast, Colorectal, Lung, Liver and Hepatobiliary and Head & Neck cancer.** However, when compared to last year, the overall number of cases in Breast cancer increased significantly by 5.97 percent, Lung cancer increased by 10.09 percent, Colorectal cancer increased by 4.68 percent, Prostate cancer increased by 1.84 percent and Liver & Hepatobiliary cancer increased by 24.80 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Headquarter (BHQ) are: Stage 0 3.49 percent, Stage I is 22.41 percent, Stage II is 22.86 percent, Stage III is 21.17 percent, and Stage IV is 20.61 percent. Unspecified stage (due to lack of pertinent information) is 8.56 percent. And in cases of Brain cancer has no stage grouping applies in AJCC Staging manual is 0.90 percent. All results are similar to 2017 staging results.

Analysis of the primary treatments modalities indicates that Surgery continues to be the majority (21 percent), followed by Radiation therapy (13 percent), Chemotherapy (4 percent), Intervention treatment (3 percent) and Concurrent chemoradiation (3 percent)

Patients who are still living after diagnosis or treatment in 2019 is 98.44 percent and patients who have died with cancer as the cause are 1.56 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 1:1 in year 2019 equal to the year 2018. The top 5 rankings of non-Thai patients are: Myanmar, Cambodia, Oman, Bangladesh and Kuwait respectively.

The Top 5 malignancies of Thai patients are:

- |   |                            |
|---|----------------------------|
| 1) Breast (Included DCIS) - 27.77 percent | 4) Prostate - 7.27 percent |
| 2) Lung - 12.50 percent                   | 5) Thyroid - 7.27 percent  |
| 3) Colorectal - 9.73 percent              |                            |

The Top 5 malignancies of non-Thai patients are:

- |   |   |
|---|---|
| 1) Breast (Included DCIS) - 20.50 percent | 4) Liver and Hepatobiliary - 8.17 percent |
| 2) Lung - 9.27 percent                    | 5) Prostate - 7.46 percent                |
| 3) Colorectal - 8.33 percent              |   |

It is the fifth time BHQ can follow the patients for 5 years and report the 5-years survival. We have shown and discussed the data of those survivors of top 3 cancers which are breast, lung and colorectal in separated chapters.




# WATTANOSOTH ANNUAL CANCER REGISTRY 2019

## DISTRIBUTION OF ALL CANCER BY AGE AND GENDER (EXCLUDED HEMATOLOGIC MALIGNANCIES)

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	5	0.55	7	0.58	12	0.57
20 - 24	3	0.33	8	0.66	11	0.52
25 - 29	13	1.44	28	2.32	41	1.94
30 - 34	23	2.54	63	5.22	86	4.07
35 - 39	23	2.54	90	7.46	113	5.35
40 - 44	33	3.65	126	10.45	159	7.53
45 - 49	75	8.29	159	13.18	234	11.08
50 - 54	80	8.84	176	14.59	256	12.13
55 - 59	93	10.28	146	12.11	239	11.32
60 - 64	133	14.70	134	11.11	267	12.65
65 - 69	147	16.24	114	9.45	261	12.36
70 - 74	136	15.03	64	5.31	200	9.47
75 - 79	72	7.96	48	3.98	120	5.68
80 - 84	38	4.20	27	2.24	65	3.08
85 - 89	23	2.54	9	0.75	32	1.52
90 - 94	6	0.66	6	0.50	12	0.57
95 +	2	0.22	1	0.08	3	0.14
<b>Total</b>	<b>905</b>	<b>100.00</b>	<b>1,206</b>	<b>100.00</b>	<b>2,111</b>	<b>100.00</b>

## DISTRIBUTION OF ALL CANCER BY AGE AND GENDER

2018




## THE TOP 10 LEADING SITE OF CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	3	0.30	529	42.05	532	23.65
C33-C34	Lung	125	12.61	115	9.14	240	10.67
C18-C20	Colorectal	114	11.50	87	6.92	201	8.94
C61	Prostate	166	16.75	0	0.00	166	7.38
C22-C24	Liver and Hepatobiliary	107	10.80	54	4.29	161	7.16
C73	Thyroid gland	41	4.14	111	8.82	152	6.76
C00-C14	Head & Neck	92	9.28	36	2.86	128	5.69
C81-C85	Lymphoma	49	4.94	35	2.78	84	3.73
C53	Cervix	0	0.00	66	5.25	66	2.93
C43-C44	Skin	45	4.54	15	1.19	60	2.67

## TOP 10 CANCER FOR ALL GENDER

All Patient




2018



## TOP 10 CANCER IN MALE


Male



2018

## TOP 10 CANCER IN FEMALE

Female




2018




## PATIENT CATEGORY OF ALL CANCER IN BANGKOK HOSPITAL HEADQUARTER

Patient treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Treatment in BHQ	398	43.98	585	48.51	983	46.57
Treatment outside BHQ	507	56.02	621	51.49	1,128	53.43
<b>Total</b>	<b>905</b>	<b>100.00</b>	<b>1,206</b>	<b>100.00</b>	<b>2,111</b>	<b>100.00</b>




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


### All Patient



### Male



### Female



Stage 0 = Carcinoma in situ

None stage = In case of Brain tumor

Unspecified stage = Incomplete staging due to insufficient patient information


## PRIMARY TREATMENT

Primary treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	155	17.13	282	23.38	437	20.70
Radiation Therapy	116	12.82	155	12.85	271	12.84
Chemotherapy	35	3.87	54	4.48	89	4.22
Concurrent chemoradiation	34	3.76	22	1.82	56	2.65
Hormonal therapy	6	0.66	10	0.83	16	0.76
Targeted therapy / Immuno therapy	6	0.66	9	0.75	15	0.71
Intervention Treatment	36	3.98	21	1.74	57	2.70
Radioactive Iodine Therapy (RAI)	10	1.10	32	2.65	42	1.99
Investigation	312	34.48	387	32.09	699	33.11
2 <sup>nd</sup> Opinion	195	21.55	234	19.40	429	20.32
<b>Total</b>	<b>905</b>	<b>100.00</b>	<b>1,206</b>	<b>100.00</b>	<b>2,111</b>	<b>100.00</b>

Surgery  
21%

2<sup>nd</sup> Opinion  
20%

Investigation  
33%



Radiation Therapy  
13%

Chemotherapy  
4%

Concurrent  
chemoradiation  
2%

Hormonal therapy  
1%

Targeted therapy/  
Immuno therapy  
1%


Intervention Treatment  
3%

Radioactive Iodine  
Therapy (RAI)  
2%




## PATIENT FOLLOW UP

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	886	97.90	1,192	98.84	2,078	98.44
Death	19	2.10	14	1.16	33	1.56
Total	905	100.00	1,206	100.00	2,111	100.00





## REFERRING HOSPITAL



BHQ = Referral in Bangkok General Hospital

PYT Group = Payathai Hospital Group

BNH = BNH Hospital

BPK = Bangkok Hospital Phuket

BHN = Bangkok Hospital Hua Hin

RPH = Royal Phnom Penh Hospital

BSH = Bangkok Hospital Samui

BKN = Bangkok Hospital Khonkhan

BSN = Bangkok Hospital Sanamchan

BHH = Bangkok Hospital Hatyai

BMR = Bangkok Hospital Muangraj

Samitivej Group = Samitivej Hospital Group

BPH = Bangkok Hospital Pattaya

Paolo Group = Paolo Hospital Group

BCH = Bangkok Hospital Chanthaburi

BRH = Bangkok Hospital Rayong

BKH = Bangkok Hospital Ratchasima

BUD = Bangkok Hospital Udon

BCM = Bangkok Hospital Chiangmai

BTH = Bangkok Trat Hospital


RAH = Royal Angkor Hospital

BPL = Bangkok Hospital Phitsanulok




## PATIENT NATIONALITY

### TOTAL PATIENT NATIONALITY



### NON-THAI PATIENT NATIONALITY




## THE TOP 10 LEADING SITE OF THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	0	0.00	271	43.29	271	27.77
C33-C34	Lung	44	12.57	78	12.46	122	12.50
C18-C20	Colorectal	51	14.57	44	7.03	95	9.73
C61	Prostate	71	20.29	0	0.00	71	7.27
C73	Thyroid gland	16	4.57	55	8.79	71	7.27
C22-C24	Liver and Hepatobiliary	38	10.86	19	3.04	57	5.84
C00-C14	Head & Neck	28	8.00	17	2.72	45	4.61
C53	Cervix	0	0.00	33	5.27	33	3.38
C81-C85	Lymphoma	15	4.29	18	2.88	33	3.38
C25	Pancreas	15	4.29	12	1.92	27	2.77

## TOP 10 CANCER OF THAI PATIENT ALL GENDER

All Gender



2018




OVERALL CANCER




## TOP 10 CANCER OF THAI PATIENT IN MALE

Male




2018




## TOP 10 CANCER OF THAI PATIENT IN FEMALE

Female



2018






## THE TOP 10 LEADING SITE OF NON-THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	3	0.47	258	40.82	261	20.50
C33-C34	Lung	81	12.64	37	5.85	118	9.27
C18-C20	Colorectal	63	9.83	43	6.80	106	8.33
C22-C24	Liver and Hepatobiliary	69	10.76	35	5.54	104	8.17
C61	Prostate	95	14.82	0	0.00	95	7.46
C00-C14	Head & Neck	64	9.98	19	3.01	83	6.52
C73	Thyroid gland	25	3.90	56	8.86	81	6.36
C81-C85	Lymphoma	34	5.30	16	2.53	50	3.93
C43-C44	Skin	39	6.08	11	1.74	50	3.93
C16	Stomach	27	4.21	16	2.53	43	3.38

## TOP 10 CANCER OF NON-THAI PATIENT ALL GENDER

All Gender




2018




## TOP 10 CANCER OF NON-THAI PATIENT IN MALE

Male



## TOP 10 CANCER OF NON-THAI PATIENT IN FEMALE

Female



## BREAST CANCER

TUMOR SITE		Number
50.0	Nipple	5
50.1	Central portion of breast	13
50.2	Upper-inner quadrant of breast	29
50.3	Lower-inner quadrant of breast	11
50.4	Upper-outer quadrant of breast	85
50.5	Lower-outer quadrant of breast	12
50.6	Axillary tail	0
50.8	Overlapping lesion of breast	41
50.9	Breast, NOS	336
Total		532


PATHOLOGY		Number
8000/3	Malignant neoplasm	119
8010/3	Carcinoma, NOS	6
8050/3	Papillary carcinoma in situ	1
8050/3	Papillary carcinoma, NOS	4
8140/3	Adenocarcinoma, NOS	2
8480/3	Mucinous carcinoma	6
8500/2	Ductal carcinoma in situ	48
8500/3	Infiltrating ductal carcinoma	330
8507/3	Invasive micropapillary carcinoma	2
8520/3	Invasive lobular carcinoma	12
8523/3	Infiltrating duct and mucinous carcinoma	1
9020/3	Malignant phyllodes tumor	1
Total		532



## AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	9	1.70	9	1.69
30 - 34	0	0.00	27	5.10	27	5.08
35 - 39	0	0.00	49	9.26	49	9.21
40 - 44	0	0.00	74	13.99	74	13.91
45 - 49	0	0.00	95	17.96	95	17.86
50 - 54	1	33.33	92	17.39	93	17.48
55 - 59	1	33.33	68	12.85	69	12.97
60 - 64	0	0.00	38	7.18	38	7.14
65 - 69	1	33.33	32	6.05	33	6.20
70 - 74	0	0.00	29	5.48	29	5.45
75 - 79	0	0.00	10	1.89	10	1.88
80 - 84	0	0.00	3	0.57	3	0.56
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	2	0.38	2	0.38
95 +	0	0.00	1	0.19	1	0.19
<b>Total</b>	<b>3</b>	<b>100.00</b>	<b>529</b>	<b>100.00</b>	<b>532</b>	<b>100.00</b>

■ Male ■ Female






## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Physician Examination = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis*

## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Stage 0 = Carcinoma in situ*

*Unspecified stage = Incomplete staging due to insufficient patient information*

## BREAST CANCER PRIMARY TREATMENT

Primary treatment	Female	
	Number	Percent
Surgery	160	60.84
Radiation therapy	71	27.00
Chemotherapy	20	7.60
Hormonal therapy	10	3.80
Targeted therapy	2	0.76
<b>Total</b>	<b>263</b>	<b>100.00</b>

Hormonal therapy

4%

Chemotherapy

7%

Radiation therapy


27%

Targeted therapy

1%


Surgery

61%



## FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Female	
	Number	Percent
Alive	261	99.24
Death	2	0.76
<b>Total</b>	<b>263</b>	<b>100.00</b>



## LUNG CANCER

TUMOR SITE		Number
34.1	Upper lobe, lung	72
34.2	Middle lobe, lung	12
34.3	Lower lobe, lung	39
34.8	Overlapping lesion of lung	2
34.9	Lung, NOS	115
Total		240


PATHOLOGY		Number
M8000/3	Malignant neoplasm	65
M8010/3	Carcinoma, NOS	3
M8021/3	Anaplastic carcinoma	2
M8033/3	Sarcomatoid carcinoma	1
M8041/3	Small cell carcinoma, NOS	8
M8046/3	Non small cell carcinoma	27
M8070/3	Squamous cell carcinoma, NOS	18
M8071/3	Squamous cell carcinoma, keratinizing, NOS	3
M8072/3	Squamous cell carcinoma, nonkeratinizing, NOS	2
M8140/3	Adenocarcinoma, NOS	99
M8246/3	Neuroendocrine carcinoma	2
M8250/3	Bronchioloalveolar carcinoma	1
M8260/3	Papillary adenocarcinoma	1
M8480/3	Mucinous adenocarcinoma	4
M8490/3	Signet ring cell adenocarcinoma	1
M8550/3	Acinar cell carcinoma	2
M8560/3	Adenosquamous carcinoma	1
Total		240




## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	3	2.61	3	1.25
35 - 39	3	2.40	1	0.87	4	1.67
40 - 44	6	4.80	4	3.48	10	4.17
45 - 49	8	6.40	9	7.83	17	7.08
50 - 54	9	7.20	14	12.17	23	9.58
55 - 59	12	9.60	19	16.52	31	12.92
60 - 64	22	17.60	24	20.87	46	19.17
65 - 69	28	22.40	19	16.52	47	19.58
70 - 74	16	12.80	7	6.09	23	9.58
75 - 79	11	8.80	10	8.70	21	8.75
80 - 84	9	7.20	4	3.48	13	5.42
85 - 89	1	0.80	1	0.87	2	0.83
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>125</b>	<b>100.00</b>	<b>115</b>	<b>100.00</b>	<b>240</b>	<b>100.00</b>

■ Male ■ Female




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Physician Examination = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis*

## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Unspecified stage = Incomplete staging due to insufficient patient information*

## LUNG CANCER PRIMARY TREATMENT

Primary treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	12	19.67	12	31.58	24	24.24
Radiation therapy	32	52.46	18	47.37	50	50.51
Chemotherapy	10	16.39	2	5.26	12	12.12
Concurrent chemoradiation	6	9.84	0	0.00	6	6.06
Targeted therapy / Immunotherapy	1	1.64	6	15.79	7	7.07
<b>Total</b>	<b>61</b>	<b>100.00</b>	<b>38</b>	<b>100.00</b>	<b>99</b>	<b>100.00</b>

Targeted therapy / Immunotherapy

7%

Concurrent chemoradiation

6%

Chemotherapy


12%

Surgery

24%


Radiation therapy

51%



## FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	57	93.44	37	97.37	94	94.95
Death	4	6.56	1	2.63	5	5.05
Total	61	100.00	38	100.00	99	100.00



## COLORECTAL CANCER

TUMOR SITE		Number
C18.0	Cecum colon	11
C18.1	Appendix	2
C18.2	Ascending colon	11
C18.3	Hepatic flexure of colon	4
C18.4	Transverse colon	7
C18.5	Splenic flexure of colon	4
C18.6	Descending colon	5
C18.7	Sigmoid colon	44
C18.8	Overl lesion of colon	1
C18.9	Colon, NOS	29
C19.9	Rectosigmoid colon	9
C20.9	Rectum	74
Total		201


PATHOLOGY		Number
M8000/3	Malignant neoplasm	47
M8010/3	Carcinoma, NOS	2
M8070/3	Squamous cell carcinoma, NOS	1
M8140/3	Adenocarcinoma	131
M8240/3	Carcinoid tumour	3
M8246/3	Neuroendocrine carcinoma, NOS	1
M8480/3	Mucinous adenocarcinoma	7
M8480/3	Mucinous carcinoma	1
M8481/3	Mucin-producing adenocarcinoma	3
M8490/3	Signet ring cell adenocarcinoma	4
M9591/3	Non-Hodgkin lymphoma, NOS	1
Total		201




## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	3	2.63	1	1.15	4	1.99
30 - 34	2	1.75	6	6.90	8	3.98
35 - 39	6	5.26	3	3.45	9	4.48
40 - 44	5	4.39	2	2.30	7	3.48
45 - 49	12	10.53	8	9.20	20	9.95
50 - 54	8	7.02	12	13.79	20	9.95
55 - 59	15	13.16	10	11.49	25	12.44
60 - 64	16	14.04	15	17.24	31	15.42
65 - 69	14	12.28	15	17.24	29	14.43
70 - 74	18	15.79	3	3.45	21	10.45
75 - 79	8	7.02	3	3.45	11	5.47
80 - 84	1	0.88	7	8.05	8	3.98
85 - 89	3	2.63	0	0.00	3	1.49
90 - 94	1	0.88	2	2.30	3	1.49
95 +	2	1.75	0	0.00	2	1.00
<b>Total</b>	<b>114</b>	<b>100.00</b>	<b>87</b>	<b>100.00</b>	<b>201</b>	<b>100.00</b>

■ Male ■ Female




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Physician Examination = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis*


## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Unspecified stage = Incomplete staging due to insufficient patient information*


## COLORECTAL CANCER PRIMARY TREATMENT

Primary treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	26	53.06	29	69.05	55	60.44
Radiation therapy	5	10.20	3	7.14	8	8.79
Chemotherapy	11	22.45	6	14.29	17	18.68
Concurrent chemoradiation	5	10.20	4	9.52	9	9.89
Intervention	2	4.08	0	0.00	2	2.20
<b>Total</b>	<b>49</b>	<b>100.00</b>	<b>42</b>	<b>100.00</b>	<b>91</b>	<b>100.00</b>



## FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	46	93.88	41	97.62	87	95.60
Death	3	6.12	1	2.38	4	4.40
Total	49	100.00	42	100.00	91	100.00



# PROSTATE CANCER


TUMOR SITE		Number
C61.9	Prostate	166
Total		166

PATHOLOGY		Number
M8000/3	Malignant neoplasm	60
M8140/3	Adenocarcinoma, NOS	53
M8550/3	Acinar adenocarcinoma	53
Total		163




## AGE AND GENDER

Age	Male	
	Number	Percent
15 - 19	0	0.00
20 - 24	0	0.00
25 - 29	0	0.00
30 - 34	1	0.60
35 - 39	0	0.00
40 - 44	0	0.00
45 - 49	0	0.00
50 - 54	4	2.41
55 - 59	14	8.43
60 - 64	26	15.66
65 - 69	44	26.51
70 - 74	44	26.51
75 - 79	19	11.45
80 - 84	9	5.42
85 - 89	4	2.41
90 - 94	1	0.60
95 +	0	0.00
<b>Total</b>	<b>166</b>	<b>100.00</b>




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Physician Examination = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis*


## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Unspecified stage = Incomplete staging due to insufficient patient information*

## PROSTATE CANCER PRIMARY TREATMENT


Type of treatment	Male	
	Number	Percent
Surgery	21	31.34
Radiation therapy	37	55.22
Hormonal therapy	6	8.96
Chemotherapy	3	4.48
<b>Total</b>	<b>67</b>	<b>100.00</b>



## FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male	
	Number	Percent
Alive	67	100.00
Death	0	0.00
<b>Total</b>	<b>67</b>	<b>100.00</b>

Alive  
100%



## HEPATOBILIARY CANCER

TUMOR SITE		Number
C22.0	Liver	129
C22.1	Intrahepatic bile duct	15
C23.9	Gallbladder	5
C24.0	Extrahepatic bile duct	3
C24.1	Ampullar of vater	9
Total		161


PATHOLOGY		Number
M8000/3	Malignant neoplasm	93
M8010/3	Carcinoma, NOS	6
M8140/3	Adenocarcinoma, NOS	16
M8160/3	Cholangiocarcinoma	5
M8170/3	Hepatocellular carcinoma, NOS	37
M8180/3	Hepatocholangiocarcinoma	1
M8246/3	Neuroendocrine carcinoma, NOS	2
M9120/3	Papillary adenocarcinoma, NOS	1
Total		161




## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	1	0.93	0	0.00	1	0.62
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	1	0.93	1	1.85	2	1.24
30 - 34	4	3.74	0	0.00	4	2.48
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	9	8.41	1	1.85	10	6.21
45 - 49	7	6.54	3	5.56	10	6.21
50 - 54	15	14.02	5	9.26	20	12.42
55 - 59	15	14.02	3	5.56	18	11.18
60 - 64	13	12.15	11	20.37	24	14.91
65 - 69	17	15.89	12	22.22	29	18.01
70 - 74	11	10.28	6	11.11	17	10.56
75 - 79	3	2.80	8	14.81	11	6.83
80 - 84	4	3.74	3	5.56	7	4.35
85 - 89	6	5.61	1	1.85	7	4.35
90 - 94	1	0.93	0	0.00	1	0.62
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>107</b>	<b>100.00</b>	<b>54</b>	<b>100.00</b>	<b>161</b>	<b>100.00</b>

■ Male ■ Female




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Physician Examination = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology*

## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



*Unspecified stage = Incomplete staging due to insufficient patient information*

## LIVER & HEPATOBILIARY CANCER PRIMARY TREATMENT

Primary treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	12	23.08	3	10.71	15	18.75
Radiation therapy	3	5.77	5	17.86	8	10.00
Chemotherapy	0	0.00	4	14.29	4	5.00
Intervention	34	65.38	16	57.14	50	62.50
Targeted therapy / Immunotherapy	3	5.77	0	0.00	3	3.75
<b>Total</b>	<b>52</b>	<b>100.00</b>	<b>28</b>	<b>100.00</b>	<b>80</b>	<b>100.00</b>


Targeted therapy / Immunotherapy  
4%

Surgery  
19%

Intervention  
62%


Radiation therapy  
10%

Chemotherapy  
5%



## FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	51	98.08	28	100.00	79	98.75
Death	1	1.92	0	0.00	1	1.25
<b>Total</b>	<b>52</b>	<b>100.00</b>	<b>28</b>	<b>100.00</b>	<b>80</b>	<b>100.00</b>




# HEMATOLOGIC MALIGNANCIES 2019

## DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES

Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	14	16.28	4	7.69	18	13.04
C82	Follicular NHL	4	4.65	3	5.77	7	5.07
C83	Diffuse NHL	26	30.23	14	26.92	40	28.99
C84	Peripheral and cutaneous T-cell lymphoma	3	3.49	6	11.54	9	6.52
C85	Other and unspecified type of NHL	2	2.33	7	13.46	9	6.52
C90	Multiple myeloma	15	17.44	10	19.23	25	18.12
C91	Lymphoid leukemia	8	9.30	2	3.85	10	7.25
C92	Myeloid leukemia	10	11.63	6	11.54	16	11.59
C93	Monocytic leukemia	1	1.16	0	0.00	1	0.72
C95	Acute leukemia, NOS	1	1.16	0	0.00	1	0.72
D46	Myelodysplastic syndrome, NOS	2	2.33	0	0.00	2	1.45
Total		86	100.00	52	100.00	138	100.00

All Patient






## DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	3	3.49	0	0.00	3	2.17
20 - 24	5	5.81	1	1.92	6	4.35
25 - 29	5	5.81	6	11.54	11	7.97
30 - 34	5	5.81	2	3.85	7	5.07
35 - 39	4	4.65	3	5.77	7	5.07
40 - 44	2	2.33	2	3.85	4	2.90
45 - 49	9	10.47	7	13.46	16	11.59
50 - 54	11	12.79	5	9.62	16	11.59
55 - 59	5	5.81	6	11.54	11	7.97
60 - 64	12	13.95	8	15.38	20	14.49
65 - 69	5	5.81	6	11.54	11	7.97
70 - 74	8	9.30	2	3.85	10	7.25
75 - 79	7	8.14	3	5.77	10	7.25
80 - 84	2	2.33	1	1.92	3	2.17
85 - 89	2	2.33	0	0.00	2	1.45
90 - 94	1	1.16	0	0.00	1	0.72
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>86</b>	<b>100.00</b>	<b>52</b>	<b>100.00</b>	<b>138</b>	<b>100.00</b>

■ Male ■ Female




## PATIENT NATIONALITY

Patient Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	27	31.40	26	50.00	53	38.41
Non-Thai	59	68.60	26	50.00	85	61.59
Total	86	100.00	52	100.00	138	100.00



## PATIENT FOLLOW UP STATUS

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	84	97.67	51	98.08	135	97.83
Death	2	2.33	1	1.92	3	2.17
<b>Total</b>	<b>86</b>	<b>100.00</b>	<b>52</b>	<b>100.00</b>	<b>138</b>	<b>100.00</b>




# LYMPHOMA

## AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	2	4.08	0	0.00	2	2.38
20 - 24	4	8.16	1	2.86	5	5.95
25 - 29	3	6.12	5	14.29	8	9.52
30 - 34	4	8.16	1	2.86	5	5.95
35 - 39	3	6.12	2	5.71	5	5.95
40 - 44	1	2.04	2	5.71	3	3.57
45 - 49	4	8.16	5	14.29	9	10.71
50 - 54	6	12.24	2	5.71	8	9.52
55 - 59	2	4.08	3	8.57	5	5.95
60 - 64	7	14.29	6	17.14	13	15.48
65 - 69	1	2.04	4	11.43	5	5.95
70 - 74	6	12.24	1	2.86	7	8.33
75 - 79	3	6.12	2	5.71	5	5.95
80 - 84	1	2.04	1	2.86	2	2.38
85 - 89	2	4.08	0	0.00	2	2.38
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>49</b>	<b>100.00</b>	<b>35</b>	<b>100.00</b>	<b>84</b>	<b>100.00</b>

■ Male ■ Female




## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Pathology of metastasis	0	0	1	7.142857	1	3.33
Pathology of primary organ	16	100.00	13	92.86	29	96.67
<b>Total</b>	<b>16</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>	<b>30</b>	<b>100.00</b>



## STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information




## TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	2	12.50	1	7.14	3	10.00
Radiation therapy	2	12.50	1	7.14	3	10.00
Chemotherapy	9	56.25	4	28.57	13	43.33
Stem cell transplantation	0	0.00	0	0.00	0	0.00
Concurrent Chemo-radiation	0	0.00	1	7.14	1	3.33
Surgery+Chemotherapy	1	6.25	0	0.00	1	3.33
Radiotherapy+Chemotherapy	1	6.25	1	7.14	2	6.67
Chemotherapy+Targetedtherapy	1	6.25	3	21.43	4	13.33
Chemotherapy+Immunotherapy	0	0.00	1	7.14	1	3.33
Radiotherapy+Chemotherapy +Targetedtherapy	0	0.00	1	7.14	1	3.33
Concurrent Chemo-radiation +Targetedtherapy	0	0.00	1	7.14	1	3.33
<b>Total</b>	<b>16</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>	<b>30</b>	<b>100.00</b>



PATIENT FOLLOW UP STATUS  
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	16	100.00	13	92.86	29	96.67
Death	0	0.00	1	7.14	1	3.33
Total	16	100.00	14	100.00	30	100.00




# MULTIPLE MYELOMA

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	0	0.00	0	0.00	0	0.00
45 - 49	2	13.33	1	10.00	3	12.00
50 - 54	2	13.33	2	20.00	4	16.00
55 - 59	2	13.33	3	30.00	5	20.00
60 - 64	2	13.33	2	20.00	4	16.00
65 - 69	2	13.33	1	10.00	3	12.00
70 - 74	1	6.67	0	0.00	1	4.00
75 - 79	3	20.00	1	10.00	4	16.00
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	1	6.67	0	0.00	1	4.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>15</b>	<b>100.00</b>	<b>10</b>	<b>100.00</b>	<b>25</b>	<b>100.00</b>


■ Male ■ Female



## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Pathology of primary organ	10	100.00	4	100.00	14	100.00
<b>Total</b>	<b>10</b>	<b>100.00</b>	<b>4</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>

Pathology of primary organ  
100%



## TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiation therapy	3	30.00	0	0.00	3	21.43
Chemotherapy	3	30.00	1	25.00	4	28.57
Targetedtherapy	2	20.00	0	0.00	2	14.29
Stem cell transplantation	0	0.00	1	25.00	1	7.14
Chemotherapy+Targetedtherapy	1	10.00	1	25.00	2	14.29
Chemotherapy+Immunotherapy	1	10.00	0	0.00	1	7.14
Chemotherapy+Stem cell transplantation	0	0.00	1	25.00	1	7.14
<b>Total</b>	<b>10</b>	<b>100.00</b>	<b>4</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>





PATIENT FOLLOW UP STATUS  
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	10	100.00	4	100.00	14	100.00
Total	10	100.00	4	100.00	14	100.00

Alive  
100%




# LEUKEMIA

## AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
15 - 19	1	5.00	0	0.00	1	3.70
20 - 24	1	5.00	0	0.00	1	3.70
25 - 29	2	10.00	1	14.29	3	11.11
30 - 34	1	5.00	1	14.29	2	7.41
35 - 39	1	5.00	1	14.29	2	7.41
40 - 44	1	5.00	0	0.00	1	3.70
45 - 49	3	15.00	1	14.29	4	14.81
50 - 54	3	15.00	1	14.29	4	14.81
55 - 59	1	5.00	0	0.00	1	3.70
60 - 64	1	5.00	0	0.00	1	3.70
65 - 69	2	10.00	1	14.29	3	11.11
70 - 74	1	5.00	1	14.29	2	7.41
75 - 79	1	5.00	0	0.00	1	3.70
80 - 84	1	5.00	0	0.00	1	3.70
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>20</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>	<b>27</b>	<b>100.00</b>

Male Female



## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Cytology	1	16.67	0	0.00	1	14.29
Pathology of primary organ	5	83.33	1	100.00	6	85.71
<b>Total</b>	<b>6</b>	<b>100.00</b>	<b>1</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>



## TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Type of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy	5	83.33	0	0.00	5	71.43
Stem cell transplantation	0	0.00	1	100.00	1	14.29
Chemotherapy+Targeted Therapy	1	16.67	0	0.00	1	14.29
<b>Total</b>	<b>6</b>	<b>100.00</b>	<b>1</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>

Chemotherapy+Targeted Therapy

14%

Stem cell transplantation

14%




Chemotherapy

72%

PATIENT FOLLOW UP STATUS  
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	5	83.33	1	100.00	6	85.71
Death	1	16.67	0	0.00	1	14.29
Total	6	100.00	1	100.00	7	100.00

Death  
14%



Alive  
86%

LEUKEMIA







## AGE DISTRIBUTION IN ALL MALE CANCER NUMBERS OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	1		0	0	0	0	0	0	0	0	0	1	0.10
C01-C02	Tongue	0	0	1	0	0	0	0	3	2	3	2	0	0	2	0	0	0	13	1.31
C03	Gum	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	2	0.20
C04	Floor of mouth	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	3	0.30
C05	Palate	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	2	0.20
C06	Other part of mouth	0	0	0	0	0	2	0	1	1	2	1	1	0	0	0	0	0	8	0.81
C07	Parotid gland	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	3	0.30
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C09	Tonsil	0	0	1	0	0	0	1	4	1	0	0	1	2	1	0	0	0	11	1.11
C10	Oropharynx	0	0	0	0	0	0	1	1	0	1	0	1	1	0	0	0	0	5	0.50
C11-C14	Head and Neck	0	1	2	2	4	5	10	5	8	3	0	2	0	1	1	0	0	44	4.44
C15	Esophagus	0	0	0	0	0	0	1	0	1	4	2	4	1	0	0	0	0	13	1.31
C16	Stomach	0	0	0	1	1	1	5	2	3	2	4	5	1	2	3	0	0	30	3.03
C17	Small Intestine	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.10
C18-C20	Colon and Rectum	0	0	3	2	6	5	12	8	15	16	14	18	8	1	3	1	2	114	11.50
C21	Anus	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	3	0.30
C22-C24	Liver and Hepatobiliary	1	0	1	4	0	9	7	15	15	13	17	11	3	4	6	1	0	107	10.80
C25	Pancreas	0	0	0	0	0	1	0	4	0	6	8	7	2	1	1	0	0	30	3.03
C26	Other and ill-defined digestive organ	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	2	0.20
C30	Nasal cavity	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2	0.20
C31	Accessory sinuses	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.10
C32	Larynx	0	0	0	0	1		1		1	2	1	2	4	1	1	1	0	15	1.51
C33-C34	Lung	0	0	0	0	3	6	8	9	12	22	28	16	11	9	1	0	0	125	12.61
C37	Thymus	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	2	0.20
C38	Mediastinum	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	3	0.30
C40-C41	Bone	1	1	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	7	0.71
C43-C44	Skin	0	0	1	0	2	2	1	1	6	4	6	11	6	3	1	1	0	45	4.54
C48	Retroperitoneum	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2	0.20
C49	Connective tissue	0	0	0	2	0	0	2	2	1	3	1	2	0	0	0	0	0	13	1.31
C50	Breast	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	3	0.30

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.10
C61	Prostate gland	0	0	0	1	0	0	0	4	14	26	44	44	19	9	4	1	0	166	16.75
C62	Testis	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	3	0.30
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	3	0	1	1	5	3	9	1	1	1	1	0	0	0	26	2.62
C66	Ureter	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	4	0.40
C67	Bladder	0	0	0	0	0	0	3	2	4	4	6	4	4	0	2	1	0	30	3.03
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	0	0	1	0	0	1	3	1	0	1	1	1	1	0	0	0	10	1.01
C72	Spinal cord and CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	3	1	2	6	3	7	4	4	2	3	1	2	3	0	0	0	0	41	4.14
C74	Adrenal gland	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	2	0.20
C79	Unknown primarysite	0	0	0	0	0	0	1	0	0	4	2	2	1	2	0	0	0	12	1.21
C81	Hodgkin's disease	1	4	2	1	1	0	2	1	2	0	0	0	0	0	0	0	0	14	1.41
C82	Follicular NHL	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	0	0	4	0.40
C83	Diffuse NHL	1	0	1	3	1	1	2	3	0	5	0	3	3	1	2	0	0	26	2.62
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	3	0.30
C85	Other and unspecified type of NHL	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.20
C90	Multiple myeloma	0	0	0	0	0	0	2	2	2	2	2	1	3	0	0	1	0	15	1.51
C91	Lymphoid leukemia	0	0	1	0	1	1	0	3	0	1	1	0	0	0	0	0	0	8	0.81
C92	Myeloid leukemia	1	0	1	1	0	0	3	0	1	0	1	0	1	1	0	0	0	10	1.01
C93	Monocytic leukemia	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.10
C95	Leukemia of unspecified cell type	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.10
D46	Myelodysplastic syndrome	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2	0.20
All ICD Group		8	8	18	28	27	45	74	91	98	145	152	145	78	40	25	7	2	991	100.00





## AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBERS OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C01-C02	Tongue	0	0	0	0	1	0	0	1	1	2	3	0	1	0	1	0	0	10	0.79
C03	Gum	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.16
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.08
C05	Palate	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	3	0.24
C06	Other part of mouth	0	0	0	0	0	0	1	2	0	0	1	0	0	0	0	0	0	4	0.32
C07	Parotid gland	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.08
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C09	Tonsil	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	2	0.16
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head and Neck	0	0	0	1	2	1	4	1	1	1	0	2	0	0	0	0	0	13	1.03
C15	Esophagus	0	0	0	0	1	0	0	0	1	1	2	0	0	0	0	0	0	5	0.40
C16	Stomach	0	1	0	0	1	2	3	2	5	4	1	2	3	1	1	1	0	27	2.15
C17	Small Intestine	0	0	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	4	0.32
C18-C20	Colon and Rectum	0	0	1	6	3	2	8	12	10	15	15	3	3	7	0	2	0	87	6.92
C21	Anus	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.08
C22-C24	Liver and Hepatobiliary	0	0	1	0	0	1	3	5	3	11	12	6	8	3	1	0	0	54	4.29
C25	Pancreas	0	0	0	0	0	1	1	5	1	5	2	3	3	1	3	0	0	25	1.99
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0.16
C31	Accessory sinuses	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	2	0.16
C32	Larynx	0	0	0	0	0	0	0	2	0	0	1	1	0	0	0	0	0	4	0.32
C33-C34	Lung	0	0	0	3	1	4	9	14	19	24	19	7	10	4	1	0	0	115	9.14
C37	Thymus	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.08
C38	Mediastinum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C40-C41	Bone	3	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	5	0.40
C43-C44	Skin	0	1	3	0	0	2	2	1	3	2	0	0	1	0	0	0	0	15	1.19
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.08
C49	Connective tissue	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	4	0.32
C50	Breast	0	0	9	25	45	69	84	85	63	35	31	26	10	3	0	2	1	488	38.79

Code	Primary site	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	3	4	7	11	7	10	7	7	5	2	2	1	0	0	0	66	5.25
C54	Corpus uteri	0	0	0	2	0	3	4	9	5	6	4	4	3	2	0	1	0	43	3.42
C55	Uterus	0	0	0	2	0	0	0	0	0	1	0	1	1	0	0	0	0	5	0.40
C56	Ovary	0	0	0	1	6	5	7	5	4	1	2	0	0	0	0	0	0	31	2.46
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.08
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	1	1	0	0	0	1	1	1	3	1	0	2	0	0	0	11	0.87
C66	Ureter	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.08
C67	Bladder	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	0	0	4	0.32
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.08
C70-C71	Brain	0	0	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4	0.32
C72	Spinal cord and CNS	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	2	0.16
C73	Thyroid gland	4	5	6	15	15	16	8	8	12	10	7	2	1	0	2	0	0	111	8.82
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.08
C79	Unknown primarysite	0	0	0	0	1	0	1	2	0	2	0	1	1	0	0	0	0	8	0.64
C81	Hodgkin's disease	0	0	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	4	0.32
C82	Follicular NHL	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	3	0.24
C83	Diffuse NHL	0	1	1	0	1	1	2	1	1	2	1	1	1	1	0	0	0	14	1.11
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	1	0	1	1	1	0	1	1	0	0	0	0	0	0	6	0.48
C85	Other and unspecified type of NHL	0	0	0	0	1	0	2	0	0	2	1	0	1	0	0	0	0	7	0.56
C90	Multiple myeloma	0	0	0	0	0	0	1	2	3	2	1	0	1	0	0	0	0	10	0.79
C91	Lymphoid leukemia	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	2	0.16
C92	Myeloid leukemia	0	0	1	1	1	0	1	1	0	0	1	0	0	0	0	0	0	6	0.48
C95	Leukemia of unspecified cell type	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
D05	Ductal carcinoma in situ of breast	0	0	0	2	4	5	11	7	5	3	1	3	0	0	0	0	0	41	3.26
D46	Myelodysplastic syndrome	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
All ICD Group		7	9	34	65	93	128	166	181	151	143	118	68	51	28	9	6	1	1,258	100.00



## A Report on Cancer Survival in Bangkok cancer hospital Wattanosoth

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Bangkok cancer hospital Wattanosoth (WSH). The data has been collected by the hospital tumor registry. The cancer patients were diagnosed during 12-month period from January 1<sup>st</sup>, 2014 to December 31<sup>st</sup>, 2019. All of them received treatment at WSH and were prospectively followed-up up to December 31<sup>st</sup>, 2019 (5-year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged  $\leq 50$  and  $> 50$  years old), sex (male and female) and stage of cancer at diagnosis (stage 1 – 4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one-month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high. Survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.





## Breast Cancer Survival


1,445 cases were diagnosed breast cancer during January 1<sup>st</sup>, 2014 to December 31<sup>st</sup>, 2019. At the time of diagnosis, 358 (24.7%) of them were at stage 1, 489 (33.8%) at stage 2, 260 (17.9%) at stage 3, and 138 (9.5%) at stage 4. Their average age was 53.4 years old (SD  $\pm$  12.1). 633 (43.8%) of them aged  $\leq$  50 years old and 812 (56.2%) aged  $>$  50 years old. Among of them, there were 5 (0.3%) males and 1,440 (99.6%) females.

The median follow-up period of these breast cancer patients was 11 months (25<sup>th</sup> – 75<sup>th</sup> percentile: 1.6 – 33 months). During the 5-year follow-up period, 27 of them were dead and 736 were lost to follow-up.

The overall observed survival rate of the breast cancer patients at 5-year follow-up period was 95.3% (95%CI: 92.6 – 97.0) (Fig.1). The survival among the male patients was 100% and female was 95.3% (95%CI: 92.5 – 97.0) (Fig.2). The male patients seem to have higher observed survival rate. The survival seems to have slightly difference between the age group of  $>$  50 and  $\leq$  50 years old, of which the survival rate was 93.3% (95%CI: 88.7 – 96.0), and 98.1% (95%CI: 95.8 – 99.2) respectively (Fig.3).

The observed survival of the early stage breast cancers, i.e., stage 1 and 2 were 98.9%, while the survival of the late stages, i.e., stage 3 and 4 was 92.9% (95%CI: 83.8 to 96.9) and 42.2% (95%CI: 9.5 to 72.9) respectively (Fig.4). The survival rate tends to be lower in the late stage breast cancers.


### Kaplan-Meier survival estimate



**Figure 1.** Overall observed survival rate of the breast cancer patients in WSH during 5-year follow-up period




## Kaplan-Meier survival estimates




**Figure 2.** Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by gender (male and female)

## Kaplan-Meier survival estimates



**Figure 3.** Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

## Kaplan-Meier survival estimates



**Figure 4.** Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

## Colorectal Cancer Survival


502 cases were diagnosed colorectal cancer during January 1<sup>st</sup>, 2014 to December 31<sup>st</sup>, 2019. At the time of diagnosis, 45 (8.9%) of them were at stage 1, 107 (21.3%) at stage 2, 187 (37.2%) at stage 3, and 140 (27.9%) at stage 4. Their average age was 60.8 years old (SD  $\pm$  13.7). 110 (21.9 %) of them aged  $\leq$  50 years old and 392 (78.0%) aged  $>$  50 years old. Among of them, there were 301 (59.9%) males and 201 (40.0%) females.

The median follow-up period of these colorectal cancer patients was 10.3 months (25<sup>th</sup> – 75<sup>th</sup> percentile: 3.6 – 30.3 months). During the 5-year follow-up period, 31 of them were dead and 251 were lost to follow-up.

The overall observed survival rate of the colorectal cancer patients at 5-year follow-up period was 83.5% (95%CI: 76.2 – 88.7) (Fig. 1). The survival among the male patients was 80.8% (95%CI: 69.9 – 88.0) and female was 87.0% (95%CI: 76.2 – 93.1) (Fig.2). The male patients seem to have lower observed survival rate. The age group of  $\leq$  50 years old seems to have higher rate of survival than the age group of  $>$  50, of which the survival rate was 94.2% (95%CI: 84.7 – 97.8) and 80.5% (95%CI: 71.6 – 86.9) respectively (Fig.3).


The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 was 90.9% (95%CI: 64.7 – 97.9) and 89.6% (95%CI: 76.1 – 95.6) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 86.5% (95%CI: 73.0 – 93.5) and 61.5% (95%CI: 33.8 – 80.4) respectively (Fig.4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.

### Kaplan–Meier survival estimate




**Figure 1.** Overall observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period

### Kaplan-Meier survival estimates




**Figure 2.** Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by gender (male and female)

### Kaplan-Meier survival estimates



**Figure 3.** Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

## Kaplan-Meier survival estimates



**Figure 4.** Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 – 4)

## Lung Cancer Survival


531 cases were diagnosed lung cancer during January 1<sup>st</sup>, 2014 to December 31<sup>st</sup>, 2019. At the time of diagnosis, 61 (11.7%) of them were at stage 1, 35 (6.6%) at stage 2, 87 (16.4%) at stage 3, and 314 (59.1%) at stage 4. Their average age was 65.5 years old (SD  $\pm 11.5$ ). 79 (14.9%) of them aged  $\leq 50$  years old and 452 (85.1%) aged  $> 50$  years old. Among of them, there were 335 (63.0%) males and 196 (36.9%) females.

The median follow-up period of these lung cancer patients was 6.6 months (25<sup>th</sup> – 75<sup>th</sup> percentile: 1.2 – 16.8 months). During the 5-year follow-up period, 57 of them were dead and 317 were lost to follow-up.

The overall observed survival rate of the lung cancer patients at 5-year follow-up period was 57.9% (95%CI: 42.5 – 70.5) (Fig.1). The survival among the male patients was 51.0% (95%CI: 27.3 – 70.6) and female was 65.8% (95%CI: 45.7 – 79.9) (Fig.2). The male patients seem to have lower observed survival rate. The survival of patients aged  $> 50$  and  $\leq 50$  years old was 58.6.0% (95%CI: 43.9 – 70.6) and 0.0% respectively (Fig.3).

The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 86.2% (95%CI: 59.3 – 95.9) and 80.0% (95%CI: 20.4 – 96.9) respectively while the survival of late stages, i.e., stage 3 and 4 was 67.3% (95%CI: 32.5 – 87.0) and 30.8% (95%CI: 7.2 – 58.9) respectively (Fig.4). The observed survival tends to be decreased as the cancer stage advanced.


### Kaplan-Meier survival estimate



**Figure 1.** Overall observed survival rate of the lung cancer patients in WSH during 5-year follow-up period




## Kaplan-Meier survival estimates




**Figure 2.** Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by gender (male and female)

## Kaplan-Meier survival estimates



**Figure 3.** Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

## Kaplan-Meier survival estimates



**Figure 4.** Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 – 4)

**BANGKOK HOSPITAL**  
**HEART HOSPITAL**  
**CANCER HOSPITAL**  
**INTERNATIONAL HOSPITAL**

CHIVA  
TRANSITIONAL CARE HOSPITAL

สมิติเวช สุขุมวิท  
SAMITVEJ SUKHUMVIT

สมิติเวช Children's HOSPITAL

สมิติเวช ศรีนครินทร์  
SAMITVEJ SRINAKARIN

สมิติเวช สุขุมวิท  
SAMITVEJ SUKHUMVIT

สมิติเวช ธนบุรี  
SAMITVEJ THONBURI

BNH HOSPITAL  
โรงพยาบาลบีเอ็นเอช

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

Paolo HOSPITAL

Paolo HOSPITAL

Paolo HOSPITAL

Paolo HOSPITAL

**BANGKOK HOSPITAL**  
SARANACHAN

โรงพยาบาลเทพารักษ์  
TAPAKORN HOSPITAL

**BANGKOK HOSPITAL**  
MUANGRAJ

**BANGKOK HOSPITAL**  
PHETCHABURI

**BANGKOK HOSPITAL**  
HUA HIN

**BANGKOK HOSPITAL**  
SAMUI

**BANGKOK HOSPITAL**  
SURAT

**BANGKOK HOSPITAL**  
PHUKET

โรงพยาบาลสิริโรจน์  
Siriraj International Hospital

โรงพยาบาลศิริราช  
SIRIRAJ HOSPITAL

**BANGKOK HOSPITAL**  
HAT YAI

**BANGKOK HOSPITAL**  
CHIANG MAI

**BANGKOK HOSPITAL**  
CHIANG RAI

**BANGKOK HOSPITAL**  
PHITSANULOK

Paolo HOSPITAL

Paolo HOSPITAL

**BANGKOK HOSPITAL**  
UDOM

**BANGKOK HOSPITAL**  
KHON KAEN

**BANGKOK HOSPITAL**  
RATCHASIMA

**BANGKOK HOSPITAL**  
PACHONG

รพ. รามาธิบดี  
RAMA BANGKOK HOSPITAL

รพ. รามาธิบดี  
RAMA BANGKOK HOSPITAL

**BANGKOK HOSPITAL**  
TRAT

**BANGKOK HOSPITAL**  
CHANTHABURI

**BANGKOK HOSPITAL**  
RAYONG

โรงพยาบาลศรีสะเกษ  
SRI RAYONG HOSPITAL

**BANGKOK HOSPITAL**  
PATTAYA

โรงพยาบาลจอนเียน  
Jomtien Hospital

สมิติเวช ชลบุรี  
SAMITVEJ CHONBURI

สมิติเวช ศรีราชา  
SAMITVEJ SRIRACHA

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

PHYATHAI HOSPITAL

HOSPITAL :

**BANGKOK HOSPITAL**

สมิติเวช  
SAMITVEJ

BNH HOSPITAL  
โรงพยาบาลบีเอ็นเอช

PHYATHAI HOSPITAL  
โรงพยาบาลฟายไธ

Paolo HOSPITAL

ROYAL BANGKOK HOSPITAL

NON HOSPITAL :

Health

MEDIC PHARMA

ANB  
A.N.B. LABORATORIES

SAVE DRUG  
A MEMBER OF BMS

BANGKOK HELICOPTER SERVICES

BANGKOK HEALTH INSURANCE

GREENLINE SYNERGY

2 Soi Soonvijai 7, New Petchburi Rd., Huaykwang, Bangkok 10310 Thailand  
 Tel: 0 2310 3000, +662 BANGKOK or 1719 (local calls only) Fax: 0 2310 3088, 0 2310 3327  
 www.wattanosothcancerhospital.com